ClinicalTrials.gg
RecruitingNCT05981326NEOEPICUREUpdated Mar 31, 2026

Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients

An interventional study of Biopsy and Blood samples in Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Other

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest — 7 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Institut Cancerologie de l'Ouest.

Planned enrollment
6th of 23
300 · median 140
Started
2023
with 1 other
No phase
19 of 35
4 open now
Primary completion
2028-04
later than 8 of 11 live
Registered
29th of 35
by date

Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, this one is the 6th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 19 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 29th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, or all of them as a file.
02

Study summary

Breast cancer (BC) is the most common cancer in women in France with nearly 58,500 new cases and 12,150 deaths estimated in 2018 .

Two major achievements have been made in the last five years for breast cancer patients. The first is therapeutic with the approval of immune checkpoint inhibitors in advanced and early triple-negative BC (TNBC) and the impressive efficacy of new antibody-drug conjugated in all BC subtypes. The second is conceptual with the generalization of adaptive therapeutic strategies guided by pathological responses after neoadjuvant therapy in early TNBC, HER2+, HR+ and BRCA mutated breast cancer. This new paradigm in the treatment of cancer patients completely redefined prognostic factors that were previously established with conventional approaches Pathological response remains a major prognostic factor especially for TNBC and HER2 early breast cancer. However, this parameter is evaluated at the end of neoadjuvant treatment and for patients with residual disease, the prognosis remains poor despite some adaptative strategies.

Our project is to integrate massive and heterogeneous data concerning the disease (clinical and biological data, imaging and histological results (with multi-omics data)) and patient's environment, personal and familial history. These data are multiple and have dynamic interactions overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the prediction of treatment response, based on clinical and molecular heterogeneous big data investigation.

The main objective of this project is to set up a clinicobiological database prospectively by collecting prospective clinical, biological, pathological and multi-omic data from 300 Patients with early BC treated at the ICO in order to define an algorithm of individual decision for the prediction of the response to this treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Neo adjuvant chemotherapy
  • Multi omic analysis
  • Predilection in silico
  • Prospective clinico database
  • Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from the patient prior to performing any protocol-related procedures, including screening , blood samples and questionnaires
  2. 18 years old or at time of written consent
  3. Patient with confirmed breast cancer
  4. Absence of disease
  5. Patient requiring chemotherapy
  6. Performance status ≤ 2 (according to WHO criteria)
  7. Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations.
  8. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  9. Patient must be affiliated to a Social Health Insurance
  10. For patients taking part in the RTW WP: working patients at time of diagnostic and in sick leave at time of inclusion

Exclusion criteria

Exclusion Criteria:

  1. Other treated within the last 5 years (except non-melanoma skin cancer or in situ carcinoma of the cervix)
  2. Non epithelial breast cancer
  3. Coagulopathy or other pathology that contraindicates procedures
  4. Pregnant or nursing patient
  5. Individual deprived of liberty or placed under the authority of a tutor
  6. Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
  7. For patients taking part in the RTW WP: patient in an "self employed" or "interim" employment situation
  8. For patients taking part in the RTW WP: Patients working part-timeProcedures for withdrawal of incorrectly enrolled patients are presented in Section 7.5.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    cohort: triple negative breast cancer

    Standard drug: Neoadjuvant treatment : Weekly paclitaxel + carboplatin + pembrolizumab (TCP) followed by EC90 \*4 pembrolizumab Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite

    Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires

  • Experimental
    cohort: HER2+ breast cancer

    Standard drug: EC100 followed by docetaxel + trastuzumab or EC100 followed by paclitaxel + trastuzumab Docetaxel + carboplatin + trastuzumab \*6 folowed by trastuzumab alone Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite

    Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires

  • Experimental
    cohort: ER/PR+ /HER2- breast cancer

    Standard drug: EC100 paclitaxel or EC100 docetaxel Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite

    Procedure: Biopsy · Procedure: Blood samples · Behavioral: Questionnaires

Interventions

  • ProcedureBiopsy

    biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment

  • ProcedureBlood samples

    Centralized blood samples will be performed at inclusion + evaluation visits

  • BehavioralQuestionnaires

    Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The accurancy predictive parameters for complete pathological response (pCR) after neoadjuvant chemotherapy

    The primary endpoint is the predictive yield of complete pathological response (pCR) after the neoaduvant treatment

    Time frame: 6 months after the initiation of neoadjuvant chemotherapy

  2. To determine the rate of Event Free Survival

    The primary endpoint is the predictive yield of Event Free Survial up to 5 years

    Time frame: 5 years after the initiation of treatment

  3. To determine the rate of Overall Survival

    The primary endpoint is the predictive yield of overall Survival up to 5 years

    Time frame: 5 years after the initiation of treatment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2028, 54 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 54 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2023
First posted
Aug 8, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2033
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981326
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Oct 31, 2023
Primary completion
Apr 2028 (estimated)
Completion
Apr 2033 (estimated)
Last update
Mar 31, 2026

Study contacts

Jean Sebastien FRENEL, MD
Contact
jean-sebastien.frenel@ico.unicancer.fr
+33240679900 ext. +33
Marine TIGREAT
Contact
marine.tigreat@ico.unicancer.fr
+33240679878 ext. +33
Jean Sebastien FRENEL, MD
study director · Institut de Cancérologie de l'Ouest

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion